FDA Approves Eli Lilly's Olumiant for Pediatric Alopecia Areata

Key Facts

1The US FDA approved Olumiant (baricitinib) for the treatment of severe alopecia areata in pediatric patients aged 12 and older.

The US FDA approved Eli Lilly's Olumiant (baricitinib) for the treatment of severe alopecia areata in pediatric patients aged 12 and older. PR Newswire reported that the approval was based on 36-week data from the BRAVE-AA-PEDS study, the largest Phase 3 trial specifically designed for pediatric patients, which demonstrated significant scalp hair regrowth and improvements in eyebrows and eyelashes.

Eli Lilly (LLY) shares closed at $1168.58 on September 25, 2026, with the session seeing a high of $1190 and a low of $1160.84. The label expansion for the drug, discovered by Incyte and licensed to Lilly, addresses early-onset alopecia areata which can be more severe and lead to extensive hair loss in younger populations.